Patients With Hepatocellular Carcinoma (HCC)

The study includes an initial screening phase aimed at assessing patient eligibility and obtaining written informed consent. Subsequently, participants will undergo centralized randomization through dedicated software, according to a procedure designed to maintain blinding for both patients and clinical staff involved in the study, with the exception of the technical personnel responsible for the preparation of fecal microbiota transplantation (FMT).

Throughout the study, both procedures included in standard clinical practice and procedures specifically required by the study protocol will be performed. Routine clinical activities will include the collection of clinical, laboratory, and instrumental data already planned within the standard patient care pathway. Laboratory monitoring will be carried out every 2-3 weeks and will include complete blood count, liver and renal function tests, C-reactive protein, urinalysis, and alpha-fetoprotein measurement. Radiological follow-up will be performed by CT scan every three months.

Regarding study-specific procedures, patients assigned to the experimental arm will receive fecal microbiota transplantation according to procedures designed to ensure maintenance of study blinding. Scheduled follow-up visits will take place at baseline and subsequently at 1, 6, and 12 months.

In addition to blood samples already collected as part of routine clinical practice, an extra 10 mL blood sample and two fecal samples will be collected from each patient at the predefined study timepoints, namely at enrollment and at months 1, 6, and 12. The analysis of biological samples, with particular focus on gut microbiota characterization and bile acid profiling, represents an important scientific investigational tool. These analyses may contribute to a better understanding of systemic inflammatory status and the pathophysiology of the gut-liver axis, potentially providing clinically relevant information for a more comprehensive and personalized long-term management of the disease.

Biological samples and patient data will be collected exclusively after obtaining written informed consent and in full compliance with the approval of the competent Territorial Ethics Committee.

Finally, the study includes prospective collection of clinical outcomes, including disease progression, radiological response according to RECIST 1.1/mRECIST criteria, and survival. Treatment efficacy will primarily be assessed in terms of progression-free survival (PFS), complemented by secondary endpoints including objective response rate (ORR), disease control rate (DCR), time to progression (TTP), and overall survival (OS).